In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CSL Limited

https://www.csl.com/

Latest From CSL Limited

Addyi Radio Ad’s Lack Of Alcohol Risk Information Elicits New Clash With US FDA

Agency directs Sprout to disseminate corrective messages about the risks associated with the female sexual dysfunction pill. Sprout previously challenged FDA’s alcohol labeling requirements.

Ad Complaints Advertising, Marketing & Sales

Gene Therapies: US FDA Clarity Needed On ‘Sameness’ Determinations For Products From Same Vector Class

Agency also should better define, and provide examples of, the types of minor differences and additional features that would affect orphan drug designation and exclusivity determinations, industry sponsors say in comments on January draft guidance.

Gene Therapy Rare Diseases

Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say

US FDA authorization will further boost already-high demand for plasma from individuals recovered from COVID-19 and increase competition for donors, NYU’s Arthur Caplan predicts, but CoVIg-19 Plasma Alliance and Emergent BioSolutions say they do not expect EUA to impact either product supply or enrollment in upcoming randomized trials of their H-Ig products.

Coronavirus COVID-19 Clinical Trials

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Other Names / Subsidiaries
    • bioCSL
    • CSL Behring
    • CSL Behring Mexico
    • CSL Biotherapies
    • CSL Bioplasma
    • Seqirus
    • Wuhan Zhong Yuan Rui De Biological Products
    • Ruide
    • Calimmune, Inc.
    • Vitaeris Inc.
    • Zenyth Therapeutics Ltd.
    • CSL, Ltd.
UsernamePublicRestriction

Register